Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

NPS+ Asthma/COPD (US) 2017

Product Code:
596200756
Publication Date:
April 2017
Format:
PDF
Price:
€2495

Is there a loyalty issue for the leading asthma/COPD brands in the US? 

With so many mono and combination therapies on offer to treat asthma and COPD, how is an abundance of choice impacting brand loyalty? What do physicians think today about the leading brands? And are they talking positively or negatively about each to their peers?

Brand marketers can find out everything they need to know about how their brand is being perceived in NPS+ Asthma/COPD (US).

This report reveals satisfaction levels, message association for key brands and how well each brand is faring in the loyalty stakes. It also shows at a glance how well a brand compares to 11 other US asthma and COPD competitors, providing crucial evidence for drug marketing strategies.

Interested in the European market? Click here to see the EU5 Edition.

Request sample pages

Insight into 12 Leading Asthma/COPD Treatments

  • Advair (fluticasone/salmeterol; GSK)
  • Anoro (umeclidinium/vilanterol; GSK)
  • Arcapta (indacaterol; Novartis)
  • Breo Ellipta (vilanterol/fluticasone furoate; GSK)
  • Daliresp (roflumilast; AstraZeneca)
  • Nucala (mepolizumab; GSK)
  • Seebri (glycopyrronium; Novartis)
  • Spiriva (tiotropium; Boehringer)
  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Tudorza (aclidinium; AstraZeneca)
  • Utibron (indacaterol/glycopyrronium; Novartis)
  • Xolair (omalizumab; Novartis/Roche)

Top Takeaways

  • Brand loyalty is hard won: Numerous choices mean that brand preference is proving difficult to secure exclusively for asthma/COPD drugs. How do individual brands compare?
  • Satisfaction with drug choice is high: However, with low loyalty for specific brands, could marketers do more to help theirs stand out from the crowd?
  • Competition is fierce: Promoters of individual brands are also promoting 5-10 others. How much share of the Promoter pool has your brand actually secured - and can more be achieved?
  • Some favourites: US Promoters of every brand covered in this report claim to promote just 2 other drugs. Which two?
  • Which brands do Detractors choose? Those who are not fans of certain brands are still favouring others. See which brands lose out and which gain.

Explore Important Brand Loyalty Issues

NPS+ Asthma/COPD (US) offers valuable insight into brand loyalty from the perspective of those currently prescribing asthma/COPD drugs to patients. You’ll discover:

  • Exactly how satisfied the US market is.
  • How loyal doctors are to your brand.
  • How many other brands your Promoters recommend.
  • Which other brands your Promoters and Detractors recommend.
  • How much market share your brand has among Promoters and Detractors.
  • How much more of a brand Promoters prescribe than Detractors.
  • Which messages Promoters, Passives and Detractors associate with your brand.
  • Your brand DNA: what doctors really think of your brand—in their own words.

A Report Based on Expert Knowledge

We surveyed 100 US Pulmonologists and General Practitioners chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between 3rd and 6th of April 2017.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:

Detractors are those who answer 0 – 6.
Passives are those who answer 7 – 8.
Promoters are those who answer 9 - 10.

How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?

NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty. 

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them. 

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.




customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved